Floatz logo

Tazemetostat

Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer InstituteSmall moleculePhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
65/ 100

Competitive context

110 Active assets in the Metastatic Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
CABAZITAXEL
AstraZeneca
Phase 4BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
BioNTech SE
Phase 4BB
Enzalutamide
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →